CSIMarket
 


Aeterna Zentaris Inc   (AEZS)
Other Ticker:  
 

Cumulative Aeterna Zentaris Inc 's Quick Ratio for Trailing Twelve Months Period

AEZS's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

AEZS Quick Ratio for Trailing Twelve Months Period

(Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Current Liabilities Growth -9.3 % -9.3 % -9.3 % -9.3 % 37.23 %
Y / Y Cash & cash equivalent Growth -23.09 % -23.09 % -23.09 % -23.09 % 763.24 %
Quick Ratio for Trailing Twelve Months Period 7.39 7.74 8.08 8.4 8.71
Total Ranking # 479 # # # 557 # 546
Seq. Current Liabilities Growth 0 % 0 % 0 % -9.3 % 0 %
Seq. Cash & cash equivalent Growth 0 % 0 % 0 % -23.09 % 0 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2022
On the trailing twelve months basis Despite year on year decrease in Aeterna Zentaris Inc 's average Current Liabilities to $7 millions, Quick Ratio for Trailing Twelve Months Period to 7.39 below company average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 190 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Aeterna Zentaris Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about AEZS
Quick Ratio AEZS in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 191
Sector # 309
S&P 500 # 466


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
8.71 4.31 1.39
(Dec 31 2021)   (Dec 31 2019)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Enliven Therapeutics Inc   20.05 
Annovis Bio inc   20.03 
Imago Biosciences Inc   20.03 
Belite Bio Inc  20.00 
Minerva Neurosciences Inc   19.92 
Anixa Biosciences Inc   19.88 
Forte Biosciences Inc   19.71 
Seres Therapeutics Inc   19.50 
Keros Therapeutics Inc   19.45 
Prometheus Biosciences Inc   19.38 
An2 Therapeutics Inc   19.08 
Rallybio Corporation  18.83 
Agios Pharmaceuticals Inc   18.81 
Medicinova Inc   18.49 
Pardes Biosciences Inc   18.39 
Verve Therapeutics Inc   18.34 
Generation Bio Co   18.32 
Lixte Biotechnology Holdings Inc   18.11 
Rapt Therapeutics Inc   18.00 
Sensei Biotherapeutics Inc   17.28 
Adicet Bio Inc   17.22 
Kinnate Biopharma Inc   17.21 
Arena Pharmaceuticals Inc   17.13 
Syndax Pharmaceuticals Inc   16.68 
Sage Therapeutics Inc   16.67 
Nkarta Inc   16.60 
Reneo Pharmaceuticals Inc   16.41 
Kalvista Pharmaceuticals Inc   16.34 
Caladrius Biosciences Inc   16.33 
Ovid Therapeutics Inc   16.26 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com